Positive kratom research deserves coverage, too. A peer-reviewed, randomized, double-blind, placebo-controlled study published in Drug Testing and Analysis provides encouraging findings about traditional kratom leaf. The trial included 116 healthy adults, with 49 receiving kratom and 67 receiving placebo. Researchers tested 0.5–4 grams of dried leaf powder, containing 6.65–53.2 mg of mitragynine, including 15 consecutive daily doses. The findings: ✅ No participants reached the study’s threshold for clinically meaningful opioid withdrawal. ✅ No serious adverse events or deaths were reported. ✅ Abuse-related adverse events were generally mild and resolved without lasting consequences. ✅ Subjective effects were modest overall, and decreased with repeated dosing. Statistically significant increases over placebo occurred only at the highest single dose. Those results deserve a place in the public conversation. The boundaries also matter: this was a short-term study of standardized leaf powder in healthy adults. It does not prove that every product, dose, or pattern of use is safe, or that dependence cannot occur. It does not establish safety for manufactured 7-OH products. As a kratom manufacturer, I welcome scrutiny. I also want reporting that gives controlled human research the attention it deserves and clearly identifies the products being discussed. To the journalists, editors, and medical commentators covering this issue: please examine this study, interview its authors, and explain its findings alongside its limitations. Public health benefits when the full evidence reaches the public. Original study: pmc.ncbi.nlm.nih.gov/article… @drdrew @AskDrDrew @DocAmen @WMCActionNews5 @nypost @washingtonpost #Kratom #KratomResearch #KratomScience #TraditionalKratom #KratomLeaf #Mitragynine #ClinicalResearch #ClinicalTrials #PeerReviewed #EvidenceBased #EvidenceBasedPolicy #PublicHealth #ConsumerSafety #BotanicalResearch #BotanicalScience #Pharmacology #Toxicology #DrugPolicy #ScienceCommunication #HealthJournalism #ResponsibleReporting #MediaAccountability #ProductStandards #ResponsibleManufacturing #ConsumerProtection